logo
ProjectEnded

Customisable Bioink Technology Platform

One of 10,000+ projects Taiyo tracks in United Kingdom.

Source: EU Funding & Tenders Portal

3D cell culture and 3D Bioprinting have become crucial to the development of health and life science research. 3D cell culture has enabled more accurate cell screening, drug and biosensor discovery, tissue engineering, and development of cell lines. One of the major challenges to culturing complex tissues is producing detailed matrix morphologies with optimised pore size, mechanical properties and

Status
Closed
Sector
Chemical (Industrial), Manufacturing (Industrial)
Location
United Kingdom
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Customisable Bioink Technology Platform

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Customisable Bioink Technology Platform” is an infrastructure initiative in the Chemical (Industrial) sector, located in United Kingdom. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

3D cell culture and 3D Bioprinting have become crucial to the development of health and life science research. 3D cell culture has enabled more accurate cell screening, drug and biosensor discovery, tissue engineering, and development of cell lines. One of the major challenges to culturing complex tissues is producing detailed matrix morphologies with optimised pore size, mechanical properties and biocompatibility. Many of the bioink 3D matrices under development do not sufficiently address the physical (mechanical properties), chemical and biological (cell-matrix interactions) complexity required for sucessful 3D culture. PGD have developed an eight amino acid sequence peptide that self-assembles and forms a hydrogel in the presence of a salt solution. This platform technology is commerically available for 3D culture or tissue engineering research and can be purchased as a liquid or spray. PGD are now investigating the feasibility of producing a bioink. PGD will produce a bioink and disposable mixing chamber that can be 3D printed and support cell viability. For additive manufacturing to break through in the life sciences and pharma industry, a complete package must be provided, including ready to use inks that are true 3D ECM mimics and compatible with processing methods. They must not impede staining/assays or optical/electrochemical detection of cells. At present, there is no bioink on the market that is suitable for large scale use in the pharmaceutical and life science industries.

Location

Country

United Kingdom (UK)

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Chemical (Industrial), Manufacturing (Industrial)

Article published date

2026-01-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project